OncoMethylome Sciences

OncoMethylome Sciences Liege (Belgium) - June 23, 2008, 08:00 CET - OncoMethylome Sciences (Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA) announced today that it entered into a supply agreement with Laboratory Corporation of America® Holdings (LabCorp®). OncoMethylome agreed to sell reagents to LabCorp for detecting methylation of the Vimentin DNA marker with Methylation-Specific PCR (MSP). LabCorp plans to initially use the reagents for laboratory-developed, stool-based testing in North America that would serve as an option for traditionally non-compliant patients recommended for colorectal cancer screening. Under terms of the agreement, OncoMethylome will earn revenue for supplying the reagents and will also qualify for milestones tied to commercial use of the reagents by LabCorp.

OncoMethylome Sciences OncoMethylome's Technology to Be Used in Merck's Clinical Trial Program with Cilengitide

OncoMethylome Sciences Liege (Belgium) - May 29, 2008, 08:00 CET - OncoMethylome Sciences (Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA) released additional data today from an ongoing clinical verification trial of their bladder cancer test.